Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC

This study has been terminated.

( DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment. )

Study NCT00338455 Information provided by Scios, Inc.

First Received on June 16, 2006. Last Updated on March 4, 2011 History of Changes

Results First Received: October 22, 2008

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator); Primary Purpose: Treatment
Conditions:	Congestive Heart Failure Cardiac Transplantation Renal Insufficiency Renal Failure
Interventions:	Drug: Natrecor (nesiritide)+Standard Care+dobutamine or milrinone Drug: Placebo+Standard Care+dobutamine or milrinone

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone	Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.
Placebo + Standard Care + Dobutamine or Milrinone	Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.

Participant Flow: Overall Study

	Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone	Placebo + Standard Care + Dobutamine or Milrinone
STARTED	9	7
COMPLETED	6	6
NOT COMPLETED	3	1
Death	2	1
Physician Decision	1	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone	Nesiritide - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.
Placebo + Standard Care + Dobutamine or Milrinone	Placebo - 28-day continuous infusion, no bolus; 3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min.

Baseline Measures

	Natrecor (Nesiritide)+Standard Care+Dobutamine or Milrinone	Placebo + Standard Care + Dobutamine or Milrinone	Total
Number of Participants [units: participants]	9	7	16
Age [units: years] Mean ± Standard Deviation	52.0 ± 9.80	54.6 ± 4.65	53.1 ± 7.85
Gender [units: participants]
Female	1	3	4
Male	8	4	12
Glomerular Filtration Rate (GFR) ^[1] [units: Participants]
GFR < 60	4	4	8
GFR > = 60	5	3	8
Body Mass Index (BMI) [units: kg/m^2] Mean ± Standard Deviation	29.4 ± 5.53	31.7 ± 5.79	30.5 ± 5.57

[1]	Estimate of the GFR using serum creatinine and demographic factors.

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Days Alive Without Renal, Hemodynamic, or Electrical Clinical Worsening Through Day 28 (Termination of Treatment) [ Time Frame: 28 days ]

Show Outcome Measure 1

2. Secondary:

Changes in Pulmonary Capillary Wedge Pressure (PCWP) [ Time Frame: 28 days ]

Show Outcome Measure 2

3. Secondary:

All Cause Mortality [ Time Frame: Day 30 and Months 2 and 6 ]

Show Outcome Measure 3

4. Secondary:

Changes in Pulmonary Artery Pressure (PAP): Systolic, Diastolic, and Mean [ Time Frame: 28 days ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination of the study due to enrollment difficulties (change in standard of care for patient population as well as changing organ allocation rules by United Network for Organ Sharing); efficacy not analyzed due to limited sample size (n=16).

Results Point of Contact:

Name/Title: Sr. Director Clinical Leader
Organization: Scios R&D, Inc.
phone: 650 564-5084

No publications provided

Responsible Party:	VP Assoc Therapeutic Area Head
ClinicalTrials.gov Identifier:	NCT00338455 History of Changes
Other Study ID Numbers:	CR003649, A051, TMAC
Study First Received:	June 16, 2006
Results First Received:	October 22, 2008
Last Updated:	March 4, 2011
Health Authority:	United States: Food and Drug Administration